A Double-Blind, Placebo-Controlled, Randomized, Multi-Center, Dose Finding Study of SLV320, a Selective A1 Adenosine Receptor Antagonist, to Evaluate the Effect on Renal Function and Safety in Subjects Hospitalized With Acute Decompensated Heart Failure and Renal Dysfunction (Reno-Defend 1).

Trial Profile

A Double-Blind, Placebo-Controlled, Randomized, Multi-Center, Dose Finding Study of SLV320, a Selective A1 Adenosine Receptor Antagonist, to Evaluate the Effect on Renal Function and Safety in Subjects Hospitalized With Acute Decompensated Heart Failure and Renal Dysfunction (Reno-Defend 1).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2013

At a glance

  • Drugs SLV 320 (Primary)
  • Indications Decompensated heart failure
  • Focus Biomarker; Pharmacodynamics
  • Acronyms Reno-Defend-1
  • Most Recent Events

    • 01 Jun 2011 Results published in American Heart Journal.
    • 18 Nov 2009 Actual number of patients (46) and actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 18 Nov 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top